AXSM
Axsome Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.68B
P/E Ratio
—
EPS
$-3.67
Beta
0.47
52W High
$191.50
52W Low
$86.99
50-Day MA
$171.53
200-Day MA
$140.07
Dividend Yield
—
Profit Margin
-28.70%
Forward P/E
333.33
PEG Ratio
0.00
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $638.50M |
| Gross Profit (TTM) | $591.02M |
| EBITDA | $-160.17M |
| Operating Margin | -18.40% |
| Return on Equity | -252.10% |
| Return on Assets | -16.80% |
| Revenue/Share (TTM) | $12.84 |
| Book Value | $1.74 |
| Price-to-Book | 97.63 |
| Price-to-Sales (TTM) | 13.60 |
| EV/Revenue | 13.34 |
| EV/EBITDA | -14.81 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 65.00% |
| Shares Outstanding | $51.15M |
| Float | $43.24M |
| % Insiders | 15.47% |
| % Institutions | 75.81% |
Analyst Ratings
Consensus ($223.66 target)
3
Strong Buy17
Buy1
HoldData last updated: 4/7/2026